We are delighted that, despite the Covid-19 crisis and lab lockdown, we have been able to raise over £1.3m mezzanine B2 funding for the continuation of our pioneering research on Alzheimer’s disease. We are very grateful to our existing investors for their continued support, as well as welcoming new subscribers. In addition, the Future Fund scheme from the UK government has proved a huge benefit in increasing incoming funds still further. In the immediate future, we shall now plan for a significant Series C round for taking to the investment community towards the end of Q1 2021.

ArabicChinese (Simplified)EnglishRussian